< 1 minute read
Feb. 9, 2022

TAK-788: an EGFR Exon 20 Insertion Mutant (EGFRex20ins) Inhibitor for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Takeda EGFRex20 Inhibitor

EGFR exon 20 mutant inhibitor, oral once-daily Breakthrough Therapy for ex20+ NSCLC (Ph. I) from cellular screening + SBDD mobocertinib ARIAD/Takeda, Cambridge, MA


Molecules of the Month

MOTY Nominees

Molecule of the Year